-
Levi & Korsinsky Notifies Geron Corporation Investors of a Class Action Lawsuit and Upcoming Deadline – GERN
04 Apr 2025 17:47 GMT
… and growth potential of Rytelo (imetelstat). Defendants’ statements included, … unmet need for the drug and to execute on … existing competition on the drug’s sales. On February … monitoring requirement necessary for the drug treatment. Following this news, the …
-
Investors in Geron Corporation Should Contact The Gross Law Firm Before May 12, 2025 to Discuss Your Rights – GERN
03 Apr 2025 17:09 GMT
… and growth potential of Rytelo (imetelstat). Defendants’ statements included, … unmet need for the drug and to execute on … existing competition on the drug’s sales. On February … monitoring requirement necessary for the drug treatment. Following this news, the …
-
Levi & Korsinsky Notifies Shareholders of Geron Corporation (GERN) of a Class Action Lawsuit and an Upcoming Deadline
01 Apr 2025 17:22 GMT
… and growth potential of Rytelo (imetelstat). Defendants’ statements included, … unmet need for the drug and to execute on … existing competition on the drug’s sales. On February … monitoring requirement necessary for the drug treatment. Following this news, the …
-
GERN INVESTOR NOTICE: Robbins Geller Rudman & Dowd LLP Announces that Geron Corporation Investors with Substantial Losses Have Opportunity to Lead Investor Class Action Lawsuit
31 Mar 2025 21:00 GMT
… product is a telomerase inhibitor, imetelstat, which Geron sells under the … significant unmet need for the drug, particularly among first-line patients … monitoring requirement necessary for the drug treatment. On this news, Geron’s …
-
GERN Stockholders Should Contact Robbins LLP for Information About How They Can Lead the Geron Corporation Class Action
31 Mar 2025 18:03 GMT
… blood cancer. Geron’s primary product is a telomerase inhibitor, imetelstat, which … significant unmet need for the drug, particularly among first-line patients … monitoring requirement necessary for the drug treatment. On this news, the price …
-
Investors in Geron Corporation Should Contact The Gross Law Firm Before May 12, 2025 to Discuss Your Rights – GERN
31 Mar 2025 17:24 GMT
… and growth potential of Rytelo (imetelstat). Defendants’ statements included, … unmet need for the drug and to execute on … existing competition on the drug’s sales. On February … monitoring requirement necessary for the drug treatment. Following this news, the …
-
GERN INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Geron Corporation Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
03 Apr 2025 20:00 GMT
… and growth potential of Rytelo (imetelstat). The Complaint alleges that Defendants … significant unmet need for the drug and to execute on its … and existing competition on the drug’s sales. What's …
-
INVESTOR ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Geron Corporation and Certain Officers – GERN
03 Apr 2025 12:00 GMT
… therapeutics for the treatment of cancer and chronic degenerative … product candidate is RYTELO (imetelstat), a telomerase inhibitor designed … Food and Drug Administration (“FDA”) for the treatment of adult … from buy to neutral, stating “[f]lat revenue trend …
-
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against XPLR, Geron, enCore, and Fluence and Encourages Investors to Contact the Firm
02 Apr 2025 01:00 GMT
… and growth potential of Rytelo (imetelstat). The Complaint alleges that Defendants … significant unmet need for the drug and to execute on its … and existing competition on the drug';s sales. For more …
-
Geron Plans to Announce First Quarter 2025 Financial Results on May 7, 2025
31 Mar 2025 20:55 GMT
… of blood cancer. Our first-in-class telomerase inhibitor RYTELO™ (imetelstat) is … the European Union for the treatment of certain adult patients with … a pivotal Phase 3 clinical trial of imetelstat in JAK-inhibitor relapsed …
About
© 1995-2025